Icon Plc (NASDAQ:ICLR) has been assigned an average rating of “Buy” from the eleven ratings firms that are covering the stock, MarketBeat.com reports. Two analysts have rated the stock with a sell rating, one has given a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. The average 1 year price objective among brokers that have covered the stock in the last year is $149.00.

Several research analysts have recently issued reports on ICLR shares. Zacks Investment Research upgraded shares of Icon from a “hold” rating to a “buy” rating and set a $163.00 target price on the stock in a report on Thursday, August 9th. BidaskClub cut shares of Icon from a “strong-buy” rating to a “buy” rating in a report on Tuesday, August 21st. KeyCorp raised their target price on shares of Icon from $152.00 to $157.00 and gave the stock an “overweight” rating in a report on Tuesday, September 11th. Robert W. Baird raised their target price on shares of Icon from $154.00 to $157.00 and gave the stock an “outperform” rating in a report on Tuesday, September 11th. Finally, UBS Group started coverage on shares of Icon in a report on Tuesday, October 9th. They issued a “sell” rating and a $145.00 target price on the stock.

NASDAQ ICLR traded down $2.33 on Friday, reaching $139.63. 563,600 shares of the company’s stock traded hands, compared to its average volume of 262,176. Icon has a 12 month low of $101.22 and a 12 month high of $155.33. The company has a debt-to-equity ratio of 0.26, a current ratio of 2.17 and a quick ratio of 2.17. The stock has a market capitalization of $7.76 billion, a P/E ratio of 25.91, a PEG ratio of 2.06 and a beta of 0.55.

Icon (NASDAQ:ICLR) last issued its quarterly earnings results on Wednesday, October 24th. The medical research company reported $1.54 EPS for the quarter, meeting analysts’ consensus estimates of $1.54. Icon had a net margin of 12.88% and a return on equity of 26.08%. The business had revenue of $655.02 million for the quarter, compared to analysts’ expectations of $654.66 million. As a group, equities analysts expect that Icon will post 6.08 earnings per share for the current fiscal year.

Institutional investors have recently modified their holdings of the company. Rehmann Capital Advisory Group boosted its holdings in Icon by 75.5% in the third quarter. Rehmann Capital Advisory Group now owns 416 shares of the medical research company’s stock valued at $64,000 after acquiring an additional 179 shares in the last quarter. DekaBank Deutsche Girozentrale boosted its holdings in Icon by 119.7% in the third quarter. DekaBank Deutsche Girozentrale now owns 769 shares of the medical research company’s stock valued at $113,000 after acquiring an additional 419 shares in the last quarter. Fort L.P. bought a new stake in Icon in the second quarter valued at $121,000. Capital Advisors Ltd. LLC bought a new stake in Icon in the third quarter valued at $121,000. Finally, Csenge Advisory Group bought a new stake in Icon in the third quarter valued at $150,000. Hedge funds and other institutional investors own 86.54% of the company’s stock.

About Icon

ICON Public Limited Company, a clinical research organization, provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries in Ireland, rest of Europe, the United States, and internationally. It specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.

Recommended Story: How is a Moving Average Calculated?

Analyst Recommendations for Icon (NASDAQ:ICLR)

Receive News & Ratings for Icon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon and related companies with MarketBeat.com's FREE daily email newsletter.